Get started

Financials · ENTA

Enanta Pharmaceuticals Inc. (ENTA) financials

For the twelve months ended Jun 30, 2026, Enanta Pharmaceuticals Inc. reported $65.26M of revenue and -$63.23M of net income.

Revenue, TTM
$65.26M
Revenue growth, YoY
+0.7%
Net income, TTM
-$63.23M
Net margin
-96.9%
Free cash flow, TTM
-$36.94M
Cash
$33.42M
P/S
5.12
Market cap
$334.1M
Annual revenue$65.32M
FY2016FY2025
Annual net income-$81.89M
FY2016FY2025
Annual free cash flow-$32.17M
FY2016FY2025

ENTA revenue and earnings growth

ENTA revenueQ3 2026$14.36M

Quarter YoY
-21.6%
QoQ
-16.3%
FY YoY
-3.4%
5Y CAGR
-11.8%
10Y CAGR
-8.6%

ENTA revenue was $14.36M in fiscal Q3 2026 (ended Jun 30, 2026), down 21.6% from a year earlier and down 16.3% from the prior quarter. For the full fiscal 2025 it was $65.32M, down 3.4% from fiscal 2024. Compound annual growth was -11.8% over 5 years and -8.6% over 10 years. It rose in 2 of the last 10 fiscal years.

ENTA net incomeQ3 2026-$19.50M

ENTA net income was -$19.50M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$18.25M a year earlier. For the full fiscal 2025 it was -$81.89M, compared with -$116.05M in fiscal 2024.

ENTA EPSQ3 2026-$0.67

ENTA diluted EPS was -$0.67 in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$0.85 a year earlier. For the full fiscal 2025 it was -$3.84, compared with -$5.48 in fiscal 2024.

ENTA free cash flowQ3 2026-$9.98M

ENTA free cash flow was -$9.98M in fiscal Q3 2026 (ended Jun 30, 2026), compared with $17.35M a year earlier. For the full fiscal 2025 it was -$32.17M, compared with -$96.71M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Revenue$65.32M$67.64M$79.20M$86.16M$97.07M$122.47M$205.20M$206.63M$102.81M$88.27M
Research and development$106.74M$131.48M$163.52M$164.52M$174.11M$136.76M$142.21M$94.86M$57.45M$40.46M
Selling, general and admin$43.93M$57.85M$52.89M$45.48M$32.54M$27.36M$26.25M$23.44M$20.75M$16.97M
Operating income-$85.35M-$121.69M-$137.21M-$123.84M-$109.57M-$41.64M$36.74M$88.33M$24.61M$30.84M
Interest expense$7.68M$10.94M$5.15M$0$0---$40.0K$45.0K
Pre-tax income-$83.55M-$117.79M-$131.00M-$122.19M-$107.58M-$35.02M$45.56M$93.12M$26.95M$32.56M
Income tax-$1.66M-$1.74M$2.82M-$433.0K-$28.58M$1.15M-$826.0K$21.16M$9.24M$10.89M
Net income-$81.89M-$116.05M-$133.82M-$121.75M-$79.00M-$36.17M$46.38M$71.96M$17.71M$21.67M
EPS, basic-$3.84-$5.48-$6.38-$5.91-$3.92-$1.81$2.37$3.74$0.93$1.14
EPS, diluted-$3.84-$5.48-$6.38-$5.91-$3.92-$1.81$2.21$3.48$0.91$1.13
Diluted shares21,33621,15720,96920,60320,17119,94021.0M20.6M19.4M19.2M

Balance sheet

Balance sheet
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Cash and equivalents$32.30M$37.23M$85.39M$43.99M$57.21M$87.13M$51.23M$63.90M$65.67M$16.58M
Receivables$6.88M$6.65M$8.61M$20.32M$23.58M$23.49M$51.31M$67.20M$10.61M$12.84M
Current assets$204.34M$299.85M$422.79M$311.71M$319.02M$436.84M$401.85M$380.39M$237.82M$232.16M
Total assets$280.73M$376.65M$462.27M$375.41M$438.79M$486.13M$489.83M$414.23M$326.64M$281.28M
Current liabilities$48.55M$57.53M$62.79M$29.83M$36.17M$24.16M$22.61M$16.02M$20.98M$7.89M
Total liabilities$216.01M$247.84M$245.54M$54.08M$39.36M$30.55M$27.34M$20.55M$24.96M$11.34M
Shareholders' equity$64.72M$128.81M$216.74M$321.33M$399.43M$455.58M$462.49M$393.68M$301.68M$269.94M

Cash flow

Cash flow
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Operating cash flow-$19.27M-$78.76M-$103.15M-$84.78M-$70.00M$7.09M$71.42M$29.22M$52.65M$35.81M
Capital expenditures$12.90M$17.95M$9.06M$2.13M$750.0K$1.45M$5.42M$2.98M$2.51M$4.74M
Free cash flow-$32.17M-$96.71M-$112.21M-$86.91M-$70.75M$5.64M$66.00M$26.24M$50.15M$31.07M
Investing cash flow$40.35M$58.23M-$53.58M$54.90M$36.99M$19.83M-$86.66M-$35.40M-$4.57M-$43.66M
Financing cash flow-$26.62M-$27.63M$198.13M$20.03M$3.08M$8.98M$2.57M$4.41M$1.02M$2.71M
Stock-based compensation$18.57M$26.80M$28.22M$26.97M$20.99M$19.57M$19.23M$15.85M$13.07M$9.35M
Depreciation and amortization$4.59M$2.34M$2.37M$2.97M$3.33M$3.64M$3.26M$2.52M$2.14M$1.66M

Key ratios

Key ratios
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Revenue growth, YoY-3.4%-14.6%-8.1%-11.2%-20.7%-40.3%-0.7%101.0%16.5%-45.1%
Net income growth, YoY-------35.5%306.3%-18.3%-72.6%
EPS growth, YoY-------36.5%282.4%-19.5%-72.4%
Operating margin-130.7%-179.9%-173.2%-143.7%-112.9%-34.0%17.9%42.7%23.9%34.9%
Net margin-125.4%-171.6%-169.0%-141.3%-81.4%-29.5%22.6%34.8%17.2%24.5%
Free cash flow margin-49.2%-143.0%-141.7%-100.9%-72.9%4.6%32.2%12.7%48.8%35.2%
Return on equity-126.5%-90.1%-61.7%-37.9%-19.8%-7.9%10.0%18.3%5.9%8.0%
Return on assets-29.2%-30.8%-28.9%-32.4%-18.0%-7.4%9.5%17.4%5.4%7.7%
Current ratio4.215.216.7310.458.8218.0817.7723.7411.3329.43

Source: XBRL data Enanta Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ENTA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ENTA$65.26M+0.7%-$63.23M-96.9%$334.1M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ENTA FAQ

7 questions
  • What is ENTA revenue?
    Enanta Pharmaceuticals Inc. (ENTA) reported $65.26M of revenue for the twelve months ended Jun 30, 2026. That is up 0.7% from the year before. Revenue for fiscal 2025 was $65.32M.
  • Is ENTA profitable?
    No. Enanta Pharmaceuticals Inc. reported a net loss of $63.23M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ENTA have?
    Enanta Pharmaceuticals Inc. reported $33.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ENTA revenue growing?
    Enanta Pharmaceuticals Inc.'s revenue changed -3.4% in fiscal 2025, to $65.32M. Its compound annual growth rate was -11.8% over 5 years and -8.6% over 10 years.
  • What is ENTA free cash flow?
    Enanta Pharmaceuticals Inc. generated -$36.94M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$35.32M less capital expenditures.
  • When did ENTA last report financial results?
    The latest statements here come from Enanta Pharmaceuticals Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this ENTA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Enanta Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.